Drug General Information
Drug ID
D06VML
Former ID
DAP001428
Drug Name
Seroxat
Synonyms
Aropax; Casbol; Frosinor; Motivan; Paroxetina; Paroxetine; Paroxetinum; PaxPar; Paxetil; Paxil; Pexeva; Paroxetine Hcl; Paxil CR;Seroxat CR; BRL 29060; FG 7051; [3H]Paroxetine; BRL-29060; FG-7051; Paroxetina [INN-Spanish]; Paroxetine (TN); Paroxetinum [INN-Latin]; Paxil (TN); NNC-20-7051; Paroxetine (USP/INN); Paroxetine [USAN:INN:BAN]; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine; (-)-Paroxetine; (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine; (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine; (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine; (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; (3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine; 3-(Benzo[1,3]Dioxol-5-Yl-Oxymethyl)-4-(4-Fluoro-Phenyl)-Piperidine Hydrochloride
Drug Type
Small molecular drug
Indication Depression [ICD9: 311; ICD10:F30-F39] Approved [537349]
Therapeutic Class
Antidepressants
Company
GlaxoSmithKline
Structure
Download
2D MOL

3D MOL

Formula
C19H20FNO3
Canonical SMILES
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
InChI
1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1
InChIKey
AHOUBRCZNHFOSL-YOEHRIQHSA-N
CAS Number
CAS 61869-08-7
PubChem Compound ID
PubChem Substance ID
ChEBI ID
ChEBI:7936
SuperDrug ATC ID
N06AB05
Target and Pathway
Target(s) Sodium-dependent serotonin transporter Target Info Modulator [556264]
KEGG Pathway Serotonergic synapse
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway 5HT1 type receptor mediated signaling pathway
5HT2 type receptor mediated signaling pathway
5HT3 type receptor mediated signaling pathway
5HT4 type receptor mediated signaling pathway
WikiPathways Monoamine Transport
SIDS Susceptibility Pathways
NRF2 pathway
Synaptic Vesicle Pathway
Serotonin Transporter Activity
References
Ref 537349Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97.
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.